4Moving Biotech is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for osteoarthritis (OA), a condition that affects nearly half of adults and is a leading cause of disability worldwide. The company's primary focus is on the clinical development of 4P004, a disease-modifying osteoarthritis drug (DMOAD) candidate. This potential long-term solution aims to address the significant unmet medical needs of OA patients by modifying the disease's progression rather than merely alleviating symptoms.

The company operates as a subsidiary of 4P-Pharma, an innovation accelerator in the biotech sector. With a team of experienced professionals, including leaders with extensive backgrounds in drug development and finance, 4Moving Biotech is positioned to advance its pipeline and contribute to the field of osteoarthritis treatment. The commitment to patient-centric solutions underscores the company's mission to enhance the quality of life for those suffering from this debilitating condition.

France

4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020. We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world.

4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.

4Moving Biotech

Company Details